lisocabtagene maraleucel 治疗复发/难治性大 B 细胞淋巴瘤

Lisocabtagene maraleucel (liso-cel) is one of the three US FDA-approved chimeric antigen receptor T-cell therapies for the treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL). TRANSCEND is the landmark trial that led to the approval of liso-cel in the third-line setting for R/R diffuse LBCL, primary mediastinal B-cell lymphoma, follicular lymphoma grade 3B and transformed lymphoma. The TRANSFORM and PILOT studies evaluated the use of liso-cel in the second-line treatment of R/R LBCL. This review details the structure and manufacturing process of liso-cel that make it distinct from other approved chimeric antigen receptor constructs, outlines results from landmark trials of liso-cel in LBCL and discusses liso-cel toxicity.

Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment for large B-cell lymphoma (LBCL). CAR T involves modifying a patient's immune cells (T cells, specifically), so that they can attack cancer cells and destroy them. Lisocabtagene maraleucel (liso-cel) is a type of CAR T-cell therapy that has been approved to treat patients with LBCL who have already received at least one line of treatment for their lymphoma.

This article outlines the structure and manufacturing process of liso-cel and discusses how it differs from other approved CAR T-cell therapies. It also summarizes the clinical data for liso-cel in the treatment of LBCL, as well as its safety and expected side effects.